State-of-the art therapy for gastrointestinal stromal tumors

被引:57
作者
Blanke, CD
Corless, CL
机构
[1] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA
[3] OHSU Canc Inst, Portland, OR USA
[4] Portland VA Med Ctr, Portland, OR USA
关键词
gastrointestinal stromal tumor; GIST; imatinib mesylate; targeted therapy;
D O I
10.1081/CNV-200055972
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Until recently, there were few effective therapeutic options for patients with gastrointestinal stromal tumors (GISTs). Most patients undergoing even potentially curative resection for early-stage disease recurred if followed for a sufficiently long period, and treatment of advanced tumors with systemic chemotherapy was ineffective. Imatinib mesylate, a molecularly targeted agent that inhibits the KIT receptor tyrosine kinase, has now been demonstrated to be highly effective at inducing objective responses in GIST patients, and it improves overall survival. In locoregional disease, ongoing studies are assessing the use of imatinib pre-or postsurgery. In addition, other agents possessing activity against a variety of molecular targets are being tested in advanced disease. Questions remain about the optimal dose of imatinib, whether to continue drug in the setting of progressive disease, and how best to prevent or overcome resistance.
引用
收藏
页码:274 / 280
页数:7
相关论文
共 43 条
[21]   Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. [J].
Joensuu, H ;
Roberts, PJ ;
Sarlomo-Rikala, M ;
Andersson, LC ;
Tervahartiala, P ;
Tuveson, D ;
Silberman, SL ;
Capdeville, R ;
Dimitrijevic, S ;
Druker, B ;
Demetri, GD .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1052-1056
[22]  
KINDBLOM LG, 2003, GASTROINTESTINAL STR
[23]   Diagnosis of submucosal tumor of the upper GI tract by endoscopic resection [J].
Kojima, T ;
Takahashi, H ;
Parra-Blanco, A ;
Kohsen, K ;
Fujita, R .
GASTROINTESTINAL ENDOSCOPY, 1999, 50 (04) :516-522
[24]   Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours [J].
Langer, C ;
Gunawan, B ;
Schüler, P ;
Huber, W ;
Füzesi, L ;
Becker, H .
BRITISH JOURNAL OF SURGERY, 2003, 90 (03) :332-339
[25]   Laparoscopic vs open resection of gastric stromal tumors [J].
Matthews, BD ;
Walsh, RM ;
Kercher, KW ;
Sing, RF ;
Pratt, BL ;
Answini, GA ;
Heniford, BT .
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2002, 16 (05) :803-807
[26]   ST1571: A paradigm of new agents for cancer therapeutics [J].
Mauro, MJ ;
O'Dwyer, M ;
Heinrich, MC ;
Druker, BJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :325-334
[27]  
MAVLIGIT GM, 1995, CANCER, V75, P2083, DOI 10.1002/1097-0142(19950415)75:8<2083::AID-CNCR2820750809>3.0.CO
[28]  
2-H
[29]   Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review [J].
Miettinen, M ;
El-Rifai, W ;
Sobin, LH ;
Lasota, J .
HUMAN PATHOLOGY, 2002, 33 (05) :478-483
[30]  
Mudan SS, 2000, CANCER, V88, P66, DOI 10.1002/(SICI)1097-0142(20000101)88:1<66::AID-CNCR10>3.0.CO